iNOS is a key mediator of anti-PD-1 melanoma therapy response
RNA-seq (gene expression) · mouse · 48 samples
- What it is
- RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
- Organism
- Mus musculus (mouse)
- Samples
- 48 samples: 48 samples, each with a distinct title — no replicated groupsGroups are read from the sample names, not from the paper. Check the list below.
- Data you can get
- A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
- Paper
- iNOS is a key mediator of anti-PD-1 melanoma therapy responseFrontiers in immunology · 2026
Read the full summary ↓
Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.
Processed table
The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.
Supplementary files
The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE334585_RAW.tar (it can run to tens of gigabytes).
Raw sequencing reads
The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.
What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.
Also filed as BioProject PRJNA1475509 and SRA study SRP707317. Searching any of these in the dataset finder brings you back here.
Any grouping that defines a comparison lives in the sample characteristics, which GEO records separately from the titles.
How we read this: Read from 48 sample titles: 48 distinct titles with little repetition. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.
- GSM9791306 S20_EXP2128RNA1_Ctrl_0hrs_1
- GSM9791307 S02_EXP2128RNA2_Ctrl_0hrs_2
- GSM9791308 S03_EXP2128RNA3_Ctrl_0hrs_3
- GSM9791309 S04_EXP2128RNA4_Ctrl_D0_1
- GSM9791310 S05_EXP2128RNA5_Ctrl_D0_2
- GSM9791311 S06_EXP2128RNA6_Ctrl_D0_4
- GSM9791312 S07_EXP2128RNA7_aPD1_D0_1
- GSM9791313 S08_EXP2128RNA8_aPD1_D0_3
- GSM9791314 S09_EXP2128RNA9_aPD1_D0_5
- GSM9791315 S10_EXP2128RNA10_IgG_D0_1
- GSM9791316 S11_EXP2128RNA11_IgG_D0_2
- GSM9791317 S12_EXP2128RNA12_IgG_D0_6
- GSM9791318 S13_EXP2128RNA13_Ctrl_D1_1
- GSM9791319 S14_EXP2128RNA14_Ctrl_D1_3
- GSM9791320 S15_EXP2128RNA15_Ctrl_D1_6
- GSM9791321 S16_EXP2128RNA16_aPD1_D1_2
- GSM9791322 S17_EXP2128RNA17_aPD1_D1_4
- GSM9791323 S18_EXP2128RNA18_aPD1_D1_5
- GSM9791324 S19_EXP2128RNA19_IgG_D1_2
- GSM9791325 S20_EXP2128RNA20_IgG_D1_4
- GSM9791326 S21_EXP2128RNA21_IgG_D1_6
- GSM9791327 S22_EXP2128RNA22_Ctrl_D3_1
- GSM9791328 S23_EXP2128RNA23_Ctrl_D3_2
- GSM9791329 S24_EXP2128RNA24_Ctrl_D3_4
- GSM9791330 S25_EXP2128RNA25_aPD1D3_3
- GSM9791331 S26_EXP2128RNA26_aPD1D3_4
- GSM9791332 S27_EXP2128RNA27_aPD1D3_5
- GSM9791333 S28_EXP2128RNA28_IgG_D3_2
- GSM9791334 S29_EXP2128RNA29_IgG_D3_3
- GSM9791335 S30_EXP2128RNA30_IgG_D3_5
- GSM9791336 S31_EXP2161RNA1_KO_Ctrl_1
- GSM9791337 S32_EXP2161RNA2_KO_Ctrl_2
- GSM9791338 S33_EXP2161RNA3_KO_Ctrl_4
- GSM9791339 S34_EXP2161RNA4_KO_aPD1_1
- GSM9791340 S35_EXP2161RNA5_KO_aPD1_2
- GSM9791341 S36_EXP2161RNA6_KO_aPD1_3
- GSM9791342 S37_EXP2161RNA7_KO_IgG_1
- GSM9791343 S38_EXP2161RNA8_KO_IgG_2
- GSM9791344 S39_EXP2161RNA9_KO_IgG_3
- GSM9791345 S40_EXP2161RNA10_WT_Ctrl_1
+ 8 more — browse all 48 samples with per-sample file links →
- GSE292614 Loss of PTDSS1 in tumor cells improves immunogenicity and response to anti-PD-1 therapy [scRNAseq] 24 samples shares anti-pd-1, therapy
- GSE314594 Cryo-thermal therapy reprograms myeloid cells into CCL5+ mature phenotype to increase T cell infiltration and potentiates anti-PD-1 therapy 18 samples shares anti-pd-1, therapy
- GSE186854 The interactions among Tumor-infiltrating T lymphocytes (TILS) induced by Stellera chamaejasme and anti-PD-1 therapy with Sing-cell Expression Profiling 10 samples shares anti-pd-1, therapy
- GSE291235 Effect of myeloid specific Trem2 knockout in hepatocellular carcinoma after anti-PD-1 therapy 30 samples shares anti-pd-1, therapy
- GSE263625 Microglial reprogramming enhances antitumor immunity and immunotherapy response in melanoma brain metastases 19 samples shares melanoma, therapy
- GSE215963 Subclonal evolution revealed by single-cell profiles of expressed mutations identifies adaptation mechanisms to immunotherapy in melanoma. 1497 samples shares melanoma, therapy
- GSE292854 Cytotoxic NK cells impede response to checkpoint immunotherapy in melanoma with an immune-excluded phenotype 10 samples shares melanoma, therapy
- GSE308848 Targeting AEBP1 to mitigate pro-tumor activity of cancer-associated fibroblasts and increase therapeutic efficacy to anti-PD-1 [scRNA-Seq] 12 samples shares anti-pd-1
Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.